Does SilverScript Cover Zepbound? Bridge, OSA, and Foundayo

SilverScript’s 2026 Part D formulary does not cover Zepbound. If you need the drug for weight management, your route is the Medicare GLP-1 Bridge, a temporary federal program that launched July 1, 2026, and pays for Zepbound outside the normal Part D benefit at a flat $50 monthly copay. If you need it for moderate-to-severe obstructive sleep apnea, you can ask SilverScript for a formulary exception and have it covered under your regular drug benefit.

Why SilverScript Won’t Cover Zepbound on Its Formulary

Federal law bars Medicare Part D plans from covering drugs prescribed solely for weight loss. In April 2025, CMS confirmed it would not finalize a proposed rule that would have lifted that restriction for 2026.1Healio. CMS Decision to Remove Obesity Drug Coverage From 2026 Final Rule Disappoints Societies Because Zepbound’s primary FDA-approved use is chronic weight management, SilverScript cannot list it for that purpose.

On top of the statutory limit, CVS Caremark (the pharmacy benefit manager behind SilverScript) removed Zepbound from its formularies effective July 1, 2025, and named Wegovy its preferred anti-obesity medication.2Mass.gov. CVS Caremark Decides to Remove Zepbound From CVS Caremark Formulary CVS Caremark later said it would add Zepbound back as a preferred option on October 1, 2026, but that reinstatement applies to commercial plans, not the Part D formulary.3Managed Healthcare Executive. CVS Caremark to Put Zepbound Back on Formulary and Add Foundayo

Getting Zepbound Through the Medicare GLP-1 Bridge

CMS created the Medicare GLP-1 Bridge to work around the Part D weight-loss ban. The program runs from July 1, 2026, through December 31, 2027, and covers Wegovy (all formulations), Zepbound (KwikPen only), and Foundayo (all formulations).4CMS. Medicare GLP-1 Bridge – Information for Providers Single-dose Zepbound vials and single-dose pens are not covered.5Medicare.gov. Weight Loss Drugs

The copay is a flat $50 per monthly fill regardless of your Part D coverage phase. Extra Help and manufacturer coupons cannot reduce it, and the amount does not count toward your Part D deductible or out-of-pocket total.6CMS. Medicare GLP-1 Bridge

Because the Bridge sits outside the Part D benefit, SilverScript carries no financial risk for it and does not have to opt in. Prior authorizations and claims go through a central system operated by Humana on behalf of CMS, so if you qualify, you can use the Bridge without any action from SilverScript itself.7Obesity Medicine Association. CMS Announces Changes to Medicare Coverage of GLP-1 Medications for 2027

Who Qualifies

You must be enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage, be 18 or older, and meet one of these BMI thresholds:6CMS. Medicare GLP-1 Bridge

  • BMI of 35 or higher, with no additional condition required.
  • BMI of 30 or higher, with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease (stage 3a or above).
  • BMI of 27 or higher, with pre-diabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

Your prescriber submits the prior authorization to the central processor and attests that you meet the criteria and have received counseling on nutrition and physical activity.8NCOA. Expanding Access to Weight Loss Medications: The Medicare GLP-1 Bridge Program

One important boundary: if you need a GLP-1 for type 2 diabetes, moderate-to-severe obstructive sleep apnea, or MASH, you are not eligible for the Bridge, because those conditions have FDA-approved indications that standard Part D plans can cover directly.4CMS. Medicare GLP-1 Bridge – Information for Providers

Getting Zepbound for Sleep Apnea Through SilverScript

Zepbound was approved by the FDA in December 2024 to treat moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first drug approved for that condition.9FDA. FDA Approves First Medication for Obstructive Sleep Apnea OSA is a medically accepted indication separate from weight loss, so Part D plans are required to consider covering Zepbound when it is prescribed for sleep apnea.10KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid

Since Zepbound still isn’t on SilverScript’s 2026 formulary, your doctor would need to file a formulary exception request. Your prescriber submits a coverage determination along with clinical documentation showing why formulary alternatives wouldn’t work. SilverScript must respond within 72 hours for a standard request or 24 hours for an expedited one. If approved, the drug is typically billed at the highest brand-tier copay for the calendar year.11SilverScript. Request for Coverage of a Non-Formulary Drug

Documentation for an OSA prior authorization generally includes your BMI, a sleep study showing moderate-to-severe OSA, a record of previous treatments tried and failed, and information about whether you use or cannot tolerate PAP therapy.12Wellcare. Does Medicare Cover Weight Loss Drugs SilverScript may apply its own clinical criteria on top of these.

What You’ll Actually Pay

Since 2025, Part D enrollees have a hard $2,000 annual cap on out-of-pocket drug spending under the Inflation Reduction Act. If you get Zepbound through a formulary exception for OSA, that cap limits your total annual exposure, and you can spread payments evenly across the year instead of absorbing a large bill upfront.13KFF. Explaining the Prescription Drug Provisions in the Inflation Reduction Act

The $2,000 cap does not apply to Zepbound obtained through the Bridge. Bridge copays sit outside Part D entirely and do not count toward your deductible or out-of-pocket total.14Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026

Eli Lilly’s commercial savings cards (which bring Zepbound down to $25 a month for some patients) are not available to you. The eligibility terms explicitly exclude anyone enrolled in Medicare, Medicaid, TRICARE, VA, or other government health programs.15Eli Lilly. Zepbound Savings For Medicare beneficiaries, the Bridge’s $50 copay is the closest equivalent to a discount.

Foundayo: A Covered Oral Alternative

Foundayo (orforglipron), an oral pill from Eli Lilly, received FDA approval on April 1, 2026, for chronic weight management in adults with obesity or overweight plus one weight-related condition.16Time. FDA Approves Eli Lilly Obesity Pill It’s covered under the Bridge at the same $50 copay, and CVS Caremark lifted its new-to-market block effective June 1, 2026.3Managed Healthcare Executive. CVS Caremark to Put Zepbound Back on Formulary and Add Foundayo

Foundayo produced about 12% average weight reduction in clinical trials, compared with more than 20% for Zepbound. It is a daily pill rather than an injection and does not require cold-chain storage.17CNBC. Eli Lilly GLP-1 Pill Foundayo Approved for Obesity If you qualify for the Bridge and prefer not to inject, it’s worth asking your doctor about.